Literature DB >> 617263

Propranolol for the control of belligerent behavior following acute brain damage.

F A Elliott.   

Abstract

The belligerence of 7 patients who had suffered an acute brain insult was effectively controlled by propranolol in doses of 60 to 320 mg per day. Of the 7 patients, 3 were treated in the acute stage after a stroke, a severe closed head injury, and a gunshot wound of the brain, respectively. A chronic postconcussion syndrome associated with chronic irritability was present in 2, and 2 were not chronically irritable but suffered from intermittent attacks of explosive rage in response to minor irritations. In all instances the belligerent behavior was controlled without inducing general sedation.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 617263     DOI: 10.1002/ana.410010516

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  6 in total

1.  Excessive aggression as model of violence: a critical evaluation of current preclinical methods.

Authors:  Klaus A Miczek; Sietse F de Boer; Jozsef Haller
Journal:  Psychopharmacology (Berl)       Date:  2013-02-21       Impact factor: 4.530

2.  Behavioral efficacy of propranolol in black patients.

Authors:  C E Schorer
Journal:  J Natl Med Assoc       Date:  1987-02       Impact factor: 1.798

3.  Aggression: psychopharmacologic management.

Authors:  P Conlon; K Frommhold
Journal:  Can Fam Physician       Date:  1989-05       Impact factor: 3.275

4.  Action of d-propranolol in manic psychoses.

Authors:  H J Möller; D von Zerssen; H M Emrich; W Kissling; C Cording; H J Schietsch; E Riedel
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1979-12

Review 5.  Coma and the etiology of violence, Part 2.

Authors:  C C Bell
Journal:  J Natl Med Assoc       Date:  1987-01       Impact factor: 1.798

Review 6.  Propranolol versus Other Selected Drugs in the Treatment of Various Types of Anxiety or Stress, with Particular Reference to Stage Fright and Post-Traumatic Stress Disorder.

Authors:  Łukasz Szeleszczuk; Dawid Frączkowski
Journal:  Int J Mol Sci       Date:  2022-09-03       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.